Abstract | OBJECTIVE: STUDY DESIGN: A cost-efficacy analysis using resource utilisation and clinical data obtained prospectively from a multicentre, randomised, double-blind, double-dummy, placebo-controlled 12-week clinical trial conducted in the US. PERSPECTIVE: Third-party payor. PATIENTS AND METHODS: RESULTS: Mean daily per person cost-efficacy ratios using improvement in forced expiratory volume in 1 second (FEV1) [> or = 12% increase from baseline] were $US 3.47 for fluticasone propionate compared with $US 7.81 for zafirlukast (1999 values). The mean daily per person cost-efficacy ratios for symptom-free days obtained were $US 5.51 for fluticasone propionate compared with $US 14.98 for zafirlukast. These cost-efficacy ratios remained in favour of fluticasone propionate after a robust sensitivity analysis. CONCLUSIONS: Treatment with fluticasone propionate 88 kg twice daily was the most cost effective treatment compared with zafirlukast 20 mg twice daily in this 12-week clinical trial. This analysis supports the use of fluticasone propionate 88 microg twice daily as first-line treatment in patients with persistent asthma previously treated with short-acting beta2-agonist alone.
|
Authors | R Menendez, R H Stanford, L Edwards, C Kalberg, K Rickard |
Journal | PharmacoEconomics
(Pharmacoeconomics)
Vol. 19
Issue 8
Pg. 865-74
( 2001)
ISSN: 1170-7690 [Print] New Zealand |
PMID | 11596838
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Anti-Asthmatic Agents
- Indoles
- Phenylcarbamates
- Sulfonamides
- Tosyl Compounds
- Fluticasone
- zafirlukast
|
Topics |
- Adult
- Androstadienes
(economics, therapeutic use)
- Anti-Asthmatic Agents
(economics, therapeutic use)
- Asthma
(drug therapy, economics)
- Cost-Benefit Analysis
- Female
- Fluticasone
- Hospitalization
(economics)
- Humans
- Indoles
- Male
- Phenylcarbamates
- Randomized Controlled Trials as Topic
- Sulfonamides
- Tosyl Compounds
(economics, therapeutic use)
- Treatment Outcome
|